Throughout 2011 and 2012, a wave of generic versions for several top-selling drugs will roll out as brand-name prescriptions go off patent.
According to the Associated Press, the magnitude of this wave of expiring drugs patents is unprecedented. [See Drug prices to plummet]
Sales for these drugs is more than $250 billion annually, and it's expected that generic competition will "decimate sales of the brand-name drugs and slash the cost to patients and companies that provide health benefits."
Recommended For You
Generics will continue to come out throughout the next decade, as about 120 brand-name prescription drugs lose market exclusivity.
Here are 5 top-selling drugs coming off patent in the next two years:
Plavix
- 2010 U.S. sales: $6.15 billion
- Condition: Anti-platelet
- Company: Bristol-Myers Squibb / Sanofi-Aventis
- Cost per month: Around $162
The anti-clot or blood thinner is the most prescribed to prevent heart attack or stroke. It is the second-best selling drug in the world, according to www.dailyfinance.com, with $9.4 billion in global sales in 2010.
(AP Photo/Mark Lennihan, File)
Lipitor
- 2010 U.S. sales: $5.33 billion
- Condition: Cholesterol
- Company: Pfizer
- Cost per month: Up to $168
Released in 1998, Lipitor had reached peak sales of $12.9 billion by 2006, according to DailyFinance.com. The website also reports that between 2010 and 2012, drugs that make up 42 percent of Pfizer's pharmaceutical revenue will lose patent protection.
(AP Photo/Mark Lennihan, file)
Seroquel
- 2010 U.S. sales: $3.75 billion
- Condition: Antipsychotic
- Company: AstraZeneca
- Cost per month: Around $549
Introduced in 1997, Seroquel (also known as Quetiapine) was set to expire in September 2011, but received a six-month extension from the FDA through a pediatric exclusivity, according to DailyFinance.com. The website also reports medicines that generated 62 percent of the British pharmaceutical's 2009 revenue will face competition from lower-priced copies by 2014.
(Photo: In this photo taken May 26, 2010, several bottles of prescription medications including quetiapine, the chemical name for the drug Seroquel, sit arranged on the kitchen table at the Cross Lanes, W. Va., home of Iraq war veteran Andrew White who died in his sleep on Feb. 12, 2008, while taking a powerful antipsychotic prescribed to treat post-traumatic stress disorder. (AP Photo/Jeff Gentner))
Actos
- 2010 U.S. sales: $3.35 billion
- Condition: Type 2 diabetes
- Company: Takeda
- Cost per month: up to $241
Launched in 1999, the Japanese-manufactured drug expired in January. But, according to DailyFinance.com, Takeda came to an agreement with generic drugmakers Ranbaxy, Watson and Mylan, and they won't start marketing Actos until August 2012. Sandoz, Teva and a few others will enter the market 180 days later.
Enbrel
- 2010 U.S. sales: $3.3 billion
- Condition: Arthritis
- Company: Amgen
- Cost per month: up to $2,784
Because Enbrel belongs to a class of medications called tumor necrosis factor or TNF-alpha inhibitors, it may be harder to duplicate. The FDA is making the process easier for the entry of generic biologics into the market, according to DailyFinance.com, but the process is just beginning.
"Both [the generic and brand-name pharmaceutical] industries are increasing their emphasis on biologic drugs, which are harder to replicate, but were recently given a 12 year limit on patent protection via the Patient Protection and Affordable Care Act," pharmaceutical analyst Sophia Snyder at research firm IBISWorld tells DailyFinance. "The brand name industry sees a lot of potential revenue here, and the generic industry is already increasing their R&D investment to find ways to create biosimilars."
© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
